<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900588</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-sPanFlu-2001</org_study_id>
    <nct_id>NCT00900588</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents</brief_title>
  <official_title>Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, stratified, randomized and double-blind phase II clinical trial was&#xD;
      conducted in adolescents to evaluate the safety and immunogenicity of a split-virion pandemic&#xD;
      influenza A vaccine (H5N1).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HI antibody and Neutralization antibody</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>10 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 microgram split-virion vaccine per dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 microgram split-virion vaccine per dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 microgram split-virion vaccine per dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 microgram whole-virion vaccine per dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)</intervention_name>
    <arm_group_label>10 ug</arm_group_label>
    <arm_group_label>15 ug</arm_group_label>
    <arm_group_label>30 ug</arm_group_label>
    <arm_group_label>5 ug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adolescent aged 12-17 years old&#xD;
&#xD;
          -  Be able to show legal identity card for the sake of recruitment&#xD;
&#xD;
          -  Volunteers or their parents are able to understand and sign the informed consent&#xD;
&#xD;
          -  Do not participate in other clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of allergic reactions&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency&#xD;
&#xD;
          -  Asthma that is unstable or required emergent care, hospitalization or intubation&#xD;
             during the past two years or that required the use of oral or intravenous&#xD;
             corticosteroids&#xD;
&#xD;
          -  Diabetes mellitus (type I or II), with the exception of gestational diabetes&#xD;
&#xD;
          -  History of thyroidectomy or thyroid disease that required medication within the past&#xD;
             12 months&#xD;
&#xD;
          -  Serious angioedema episodes within the previous 3 years or requiring medication in the&#xD;
             previous two years&#xD;
&#xD;
          -  Hypertension that was not well controlled by medication or the blood pressure is more&#xD;
             than 145/95 mmHg at enrollment&#xD;
&#xD;
          -  Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions) or significant bruising or bleeding&#xD;
             difficulties with IM injections or blood draws&#xD;
&#xD;
          -  Active malignancy or treated malignancy for which there is not reasonable assurance of&#xD;
             sustained cure or malignancy that is likely to recur during the period of study&#xD;
&#xD;
          -  Seizure disorder other than:&#xD;
&#xD;
               1. Febrile seizures under the age of two years old&#xD;
&#xD;
               2. Seizures secondary to alcohol withdrawal more than 3 years ago, or&#xD;
&#xD;
               3. A singular seizure not requiring treatment within the last 3 years&#xD;
&#xD;
          -  Asplenia, functional asplenia or any condition resulting in the absence or removal o&#xD;
             the spleen&#xD;
&#xD;
          -  Guillain-Barre Syndrome&#xD;
&#xD;
          -  Any history of immunosuppressive medications or cytotoxic medications or inhaled&#xD;
             corticosteroids within the past six months (with the exception of corticosteroid nasal&#xD;
             spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated&#xD;
             dermatitis)&#xD;
&#xD;
          -  History of any blood products administration within 3 months before the dosing&#xD;
&#xD;
          -  Administration of any other investigational research agents within 30 days before the&#xD;
             dosing&#xD;
&#xD;
          -  Administration of any live attenuated vaccine within 30 days before the dosing&#xD;
&#xD;
          -  Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or&#xD;
             allergy treatment with antigen injections, within 14 days before the dosing&#xD;
&#xD;
          -  Be receiving anti-TB prophylaxis or therapy currently&#xD;
&#xD;
          -  Axillary temperature &gt; 37.0 centigrade at the time of dosing&#xD;
&#xD;
          -  Psychiatric condition that precludes compliance with the protocol:&#xD;
&#xD;
               1. Past or present psychoses&#xD;
&#xD;
               2. Past or present bipolar disorder requiring therapy that has not been well&#xD;
                  controlled on medication for the past two years&#xD;
&#xD;
               3. Disorder requiring lithium&#xD;
&#xD;
               4. Suicidal ideation occurring within five years prior to enrollment&#xD;
&#xD;
          -  Any medical, psychiatric, social condition, occupational reason or other&#xD;
             responsibility that, in the judgment of the investigator, is a contraindication to&#xD;
             protocol participation or impairs a volunteer's ability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Centers for Diseases Control and Prevention</name>
      <address>
        <city>Beijing</city>
        <zip>100013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>May 12, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <last_update_submitted>August 10, 2009</last_update_submitted>
  <last_update_submitted_qc>August 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2009</last_update_posted>
  <keyword>immunogenictiy</keyword>
  <keyword>safety</keyword>
  <keyword>pandemic influenza A vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

